SEC Form 4 · accession 0000886163-15-000048
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason Aryeh
Director
Period of report
Apr 24, 2015
Accepted (ET)
Apr 27, 2015 · 7:54 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 24, 2015 | A | 925 | $0.00 | A | 58,337 | D | |
| Common StockF2 | holding | — | — | — | 255,716 | I | Indirect | |
| Common Stock | holding | — | — | — | 5,025 | I | by Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F3 | $89.75 | Apr 24, 2015 | A | 2,754 | A | — | Apr 24, 2025 | Common Stock | 2,754 | 2,754 | D |
Explanation of responses
- F1Acquired by a grant of the Board of Directors of the Company at their annual meeting on April 24, 2015. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
- F2All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds.
- F3Acquired by a grant of the Board of Directors of the Company at their annual meeting on April 24, 2015. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.